Table 2 Comparison of the prevalence of MTP joint and foot specific US detectable and clinically detectable pathology of the study participants at baseline and twelve weeks by frequency (N)
Variable | Â | Baseline | 12 weeks | Statistical Values |
|---|---|---|---|---|
MTP joint synovial hypertrophy (US) | R2 | 58.1% (18) | 45.2% (14) | p = 1.000 |
| Â | R5 | 74.2% (23) | 51.6% (16) | p = 0.344 |
| Â | L2 | 61.3% (19) | 35.5% (11) | p = 0.267 |
| Â | L5 | 67.7% (21) | 54.8% (17) | p = 0.754 |
MTP joint synovitis (Doppler US) | R2 | 6.5% (2) | 6.5% (2) | p = 1.000 |
| Â | R5 | 9.7% (3) | 3.2% (1) | p = 0.625 |
| Â | L2 | 3.2% (1) | 0% (0) | p = 1.000 |
| Â | L5 | 9.7% (3) | 6.5% (2) | p = 1.000 |
MTP joint erosion (US) | R2 | 25.8% (8) | 25.8% (8) | p = 0.250 |
| Â | R5 | 74.2% (23) | 51.6% (16) | p = 0.727 |
| Â | L2 | 9.7% (3) | 12.9% (4) | p = 1.000 |
| Â | L5 | 61.3% (19) | 58.1% (18) | p = 1.000 |
Plantar forefoot bursal hypertrophy (US) | R | 83.9% (26) | 67.7% (21) | p = 1.000 |
| Â | L | 80.6% (25) | 69.2% (18) | p = 0.508 |
Clinically detectable plantar forefoot bursae | R | 41.9% (13) | 32.3% (10) | p = 0.012 |
| Â | L | 35.5% (11) | 19.4% (6) | p = 0.453 |
Clinically detectable MTP joint synovitis | R | 45.2% (14) | 25.8% (8) | p = 0.375 |
| Â | L | 25.8% (8) | 16.1% (5) | p = 0.070 |